Clinical Study of the Effect of Combined Treatment of Aspirin and Zileuton on Biomarkers of Tobacco-Related Carcinogenesis in Current Smokers

Trial Profile

Clinical Study of the Effect of Combined Treatment of Aspirin and Zileuton on Biomarkers of Tobacco-Related Carcinogenesis in Current Smokers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Zileuton (Primary) ; Aspirin
  • Indications Lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Sep 2017 Planned number of patients changed from 56 to 66.
    • 21 Sep 2017 Planned primary completion date changed from 28 Feb 2018 to 31 Jan 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top